Trade Baudax Bio, Inc. - BXRX CFD
Add to favourite- Summary
- Historical Data
- Events
- Ownership
| Spread | 0.0400 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 1.7445 |
| Open* | 1.6249 |
| 1-Year Change* | -4.42% |
| Day's Range* | 1.565 - 1.6447 |
| 52 wk Range | N/A |
| Average Volume (10 days) | N/A |
| Average Volume (3 months) | N/A |
| Market Cap | N/A |
| P/E Ratio | N/A |
| Shares Outstanding | N/A |
| Revenue | N/A |
| EPS | N/A |
| Dividend (Yield %) | N/A |
| Beta | N/A |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2023 | 1.7445 | -0.2592 | -12.94% | 2.0037 | 2.0435 | 1.5550 |
| Mar 27, 2023 | 1.9239 | 0.2093 | 12.21% | 1.7146 | 2.0535 | 1.5550 |
| Mar 24, 2023 | 1.5351 | 0.0399 | 2.67% | 1.4952 | 1.6348 | 1.4852 |
| Mar 23, 2023 | 1.5251 | -0.0200 | -1.29% | 1.5451 | 1.5451 | 1.4852 |
| Mar 22, 2023 | 1.5451 | 0.0001 | 0.01% | 1.5450 | 1.6348 | 1.5450 |
| Mar 21, 2023 | 1.5650 | -0.0199 | -1.26% | 1.5849 | 1.6647 | 1.5450 |
| Mar 20, 2023 | 1.5850 | -0.1394 | -8.08% | 1.7244 | 1.7943 | 1.5450 |
| Mar 17, 2023 | 1.7444 | 0.0100 | 0.58% | 1.7344 | 1.8641 | 1.5251 |
| Mar 16, 2023 | 1.8840 | 0.5483 | 41.05% | 1.3357 | 2.1233 | 1.3357 |
| Mar 15, 2023 | 1.3058 | -0.0598 | -4.38% | 1.3656 | 1.3656 | 1.2360 |
| Mar 14, 2023 | 1.3557 | 0.0200 | 1.50% | 1.3357 | 1.4055 | 1.3157 |
| Mar 13, 2023 | 1.3257 | -0.0200 | -1.49% | 1.3457 | 1.3756 | 1.2858 |
| Mar 10, 2023 | 1.3257 | -0.1794 | -11.92% | 1.5051 | 1.5052 | 1.2659 |
| Mar 9, 2023 | 1.5550 | -0.1296 | -7.69% | 1.6846 | 1.6846 | 1.5251 |
| Mar 8, 2023 | 1.6747 | -0.0099 | -0.59% | 1.6846 | 1.7245 | 1.6646 |
| Mar 7, 2023 | 1.7046 | -0.0298 | -1.72% | 1.7344 | 1.7644 | 1.6447 |
| Mar 6, 2023 | 1.7245 | -0.0100 | -0.58% | 1.7345 | 1.7345 | 1.6048 |
| Mar 3, 2023 | 1.7544 | -0.0298 | -1.67% | 1.7842 | 1.8840 | 1.7543 |
| Mar 2, 2023 | 1.8142 | -0.1496 | -7.62% | 1.9638 | 1.9738 | 1.7942 |
| Mar 1, 2023 | 1.9837 | -0.1994 | -9.13% | 2.1831 | 2.1831 | 1.9438 |
Baudax Bio, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Baudax Bio, Inc. Company profile
About Baudax Bio Inc
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. The injectable form of IV meloxicam, which utilizes NanoCrystal technology, increases overall drug solubility that provides a faster onset of action of meloxicam and provides a rapid treatment of acute pain. Its product pipeline includes Neuromuscular blocking agents (NMBAs), which are used as muscle paralyzing agents to facilitate intubation and surgery. The Company is developing intermediate-acting NMBA, BX1000, an ultrashort-acting NMBA, BX2000, and a reversal agent specific to its NMBAs. Its other products include Dex-IN, which is a selective alpha-2 adrenergic agonist that has sedative, analgesic, and anxiolytic properties.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Baudax Bio Inc revenues increased from $493K to $1.1M. Net loss applicable to common stockholders decreased 71% to $22.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Fair Value Adjustments on Other Assets decrease from $2.2M (expense) to $33.3M (income).
News
Mask network price prediction: What is mask network (MASK)?
Can MASK – the native token of the Mask Network protocol – continue its recent growth?
12:42, 29 March 2023
Natural gas price forecast 2030-2050: What next for gas prices?
Where will natural gas prices head in 2023 and beyond?
17:27, 28 March 2023
Terra price prediction: What is terra (LUNA)?
What happens next to LUNA after Do Kwon's arrest?
14:22, 28 March 2023
Bitgert price prediction: Where next for BRISE?
BRISE outperformed the market in 2022, but there are some red flags
12:49, 28 March 2023
XRP price prediction: How will the court case affect the price of ripple?
As its ongoing court case looks set to conclude, what might be next for XRP?
11:13, 28 March 2023
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
10:10, 28 March 2023
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com